A combination of zanzalintinib and atezolizumab has been found to improve survival in patients with colorectal cancer. This development may expand the role of tyrosine kinase inhibitors in treating solid tumors. The combination's effectiveness suggests a potential advancement in treatment options for certain cancer patients.